Commercialization Updates. For any Calendar Year prior to the end of the ER Royalty Term, FDC Royalty Term or Proprietary Non-Donepezil FDC Royalty Term, as applicable, in which Forest or its Affiliates or Sublicensees is Commercializing a Product in the Field in the Territory, Forest shall, on [*] basis, provide Adamas with a reasonably detailed report describing such Commercialization activities completed since the last report and planned for the next [*], no later than [*]. Following the receipt of the first approval by the FDA of an NDA for the first Memantine-Donepezil FDC Product in the Field in the Territory, the Parties shall meet [*] during each Calendar Year to discuss the Commercialization of the Products in the Field [*].
Commercialization Updates. AZ shall keep the JSC fully informed regarding the progress of all material commercialization activities for the Products in the Territory.
Commercialization Updates. Impax shall, through the JMC (or directly, if JMC is terminated), keep Durect appropriately and routinely informed regarding progress with respect to its Commercialization of the Product in the Territory.
Commercialization Updates. Legend shall keep Noile informed of its Commercialization of any Licensed Product and shall provide [***] updates to Noile summarizing progress in the Development and Commercialization of any Licensed Products in relation to which any Research and Development Plan has been completed. All such updates shall be considered Legend’s Confidential Information and, as between the Parties, shall be exclusively owned by Legend.
Commercialization Updates. Novartis shall keep MPAG reasonably informed of Novartis’, its Affiliates’ and their respective sublicensees’ Commercialization activities with respect to the Products by providing updates through the Governance Committee at least [***] per Calendar Year. Upon MPAG’s request (which may be made no more than [***] per Calendar Year) such updates shall include the amount of Net Sales of Products in each country in the Territory other than the Commercial Territories. 264813180 v3
Commercialization Updates. CAMP4 will provide OPKO with an annual report summarizing its Commercialization activities for the Licensed Products in the Field in the Territory. Such reports will be Confidential Know-How of CAMP4 and subject to the terms of ARTICLE 11 (Confidentiality).
Commercialization Updates. For any Calendar Year prior to the end of the ER Royalty Term, FDC Royalty Term or Proprietary Non-Donepezil FDC Royalty Term, as applicable, in which Forest or its Affiliates or Sublicensees is Commercializing a Product in the Field in the Territory, Forest shall, on [ * ] basis, provide Adamas with a reasonably detailed report describing such Commercialization activities completed since the last report and planned for the next [ * ], no later than [ * ]. Following the receipt of the first approval by the FDA of an NDA for the first Memantine-Donepezil FDC Product in the Field in the Territory, the Parties [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. shall meet [ * ] during each Calendar Year to discuss the Commercialization of the Products in the Field [ * ].
Commercialization Updates. Upon the request of ImmunoGen, Jazz shall provide ImmunoGen with brief written reports, which ImmunoGen may request no more frequently than [***] per Calendar Year, that summarize Jazz’s efforts to Commercialize the Portions of this Exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Licensed Product in the Jazz Territory in sufficient detail to establish that Jazz is [***] to Commercialize the Licensed Product in the Jazz Territory.
Commercialization Updates. Each Party shall keep the JPC reasonably informed on the Commercialization activities performed by such Party in the Co-Development Territory under this Agreement. Without limiting the foregoing, at each regularly scheduled JPC meeting, each Party shall provide the JPC with a summary report of the Commercialization or manufacturing activity performed by it in the Co-Development Territory since the last JPC meeting and the results thereof. The JPC shall discuss the progress and results of the Parties’ Commercialization or manufacturing activity in the Co-Development Territory and each Party shall promptly respond to the other Portions of this Exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Party’s reasonable questions or requests for additional information relating to such Commercialization in the Co-Development Territory.
Commercialization Updates. Each Party will, in connection with meetings of the JPC, provide updates on any Commercialization activities undertaken by or on behalf of such Party with respect to the Praluent Products in [* * *] since the preceding meeting (or, in the case of the first meeting of the JPC, since the Transition Date) that such Party reasonably determines could have a material impact on the other Party’s Development or Commercialization of any Praluent Product or on any Marketing Approvals in such other Party’s Territory. Without limiting the foregoing, if a Party plans to withdraw a Marketing Approval for a Praluent Product in the Regeneron Territory, in the case of Regeneron, or in [* * *], in the case of Sanofi, such Party shall provide prior written notice of such withdrawal to the other Party at least [* * *] days in advance of such withdrawal. For the avoidance of doubt, the updates and notices provided pursuant to this Section 5.3 are for informational purposes only and do not grant the receiving Party the right to comment on, approve or object to the update or notice provided by the other Party. A Party’s inadvertent failure to provide to the other Party any update or notice described in this Section 5.3 shall not be grounds for termination by such other Party.
